REGENXBIO Inc. (RGNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
RGNX POWR Grades
- Value is the dimension where RGNX ranks best; there it ranks ahead of 99.01% of US stocks.
- RGNX's strongest trending metric is Quality; it's been moving up over the last 177 days.
- RGNX ranks lowest in Growth; there it ranks in the 4th percentile.
RGNX Stock Summary
- Of note is the ratio of REGENXBIO INC's sales and general administrative expense to its total operating expenses; merely 12.7% of US stocks have a lower such ratio.
- Over the past twelve months, RGNX has reported earnings growth of -160.41%, putting it ahead of only 9.79% of US stocks in our set.
- As for revenue growth, note that RGNX's revenue has grown 415.41% over the past 12 months; that beats the revenue growth of 97.49% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to REGENXBIO INC, a group of peers worth examining would be TSVT, CRUS, MRUS, AGIO, and SELB.
- Visit RGNX's SEC page to see the company's official filings. To visit the company's web site, go to www.regenxbio.com.
RGNX Valuation Summary
- In comparison to the median Healthcare stock, RGNX's EV/EBIT ratio is 13.13% lower, now standing at 8.6.
- Over the past 89 months, RGNX's EV/EBIT ratio has gone up 55.4.
Below are key valuation metrics over time for RGNX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| RGNX | 2023-01-20 | 2.1 | 1.8 | 13.5 | 8.6 |
| RGNX | 2023-01-19 | 2.0 | 1.7 | 13.3 | 8.4 |
| RGNX | 2023-01-18 | 2.1 | 1.8 | 13.5 | 8.5 |
| RGNX | 2023-01-17 | 2.1 | 1.8 | 13.8 | 8.7 |
| RGNX | 2023-01-13 | 2.2 | 1.9 | 14.4 | 9.2 |
| RGNX | 2023-01-12 | 2.2 | 1.9 | 14.3 | 9.1 |
RGNX Growth Metrics
- Its 3 year revenue growth rate is now at 444.47%.
- Its 4 year cash and equivalents growth rate is now at -14.01%.
- The 2 year revenue growth rate now stands at 811.05%.
The table below shows RGNX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 480.034 | 158.121 | 73.637 |
| 2022-06-30 | 484.295 | 172.218 | 90.716 |
| 2022-03-31 | 473.681 | 204.095 | 101.256 |
| 2021-12-31 | 470.347 | 218.875 | 127.84 |
| 2021-09-30 | 93.137 | -67.894 | -212.424 |
| 2021-06-30 | 161.276 | -67.995 | -145.228 |
RGNX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- RGNX has a Quality Grade of D, ranking ahead of 18.52% of graded US stocks.
- RGNX's asset turnover comes in at 0.116 -- ranking 250th of 682 Pharmaceutical Products stocks.
- PTGX, ARDX, and CBAY are the stocks whose asset turnover ratios are most correlated with RGNX.
The table below shows RGNX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.116 | 0.581 | -0.362 |
| 2021-06-30 | 0.218 | 0.738 | -0.257 |
| 2021-03-31 | 0.242 | 0.762 | -0.255 |
| 2020-12-31 | 0.286 | 0.769 | -0.281 |
| 2020-09-30 | 0.297 | 0.798 | -0.244 |
| 2020-06-30 | 0.126 | 0.763 | -0.367 |
RGNX Price Target
For more insight on analysts targets of RGNX, see our RGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $64.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
RGNX Stock Price Chart Interactive Chart >
RGNX Price/Volume Stats
| Current price | $23.13 | 52-week high | $35.73 |
| Prev. close | $23.00 | 52-week low | $18.69 |
| Day low | $22.75 | Volume | 295,100 |
| Day high | $23.29 | Avg. volume | 306,433 |
| 50-day MA | $22.78 | Dividend yield | N/A |
| 200-day MA | $25.27 | Market Cap | 1.00B |
REGENXBIO Inc. (RGNX) Company Bio
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The company was founded in 2009 and is based in Rockville, Maryland.
Latest RGNX News From Around the Web
Below are the latest news stories about REGENXBIO INC that investors may wish to consider to help them evaluate RGNX as an investment opportunity.
Rockville biotech RegenxBio launches clinical trial in muscular dystrophyIt's one of a series of treatments the company is developing as it aims to bring multiple products to market by 2025. |
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting PatientsREGENXBIO Inc. (Nasdaq: RGNX) today announced that the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment of Duchenne muscular dystrophy (Duchenne) is now active and recruiting patients. RGX-202 is designed to deliver a transgene for a novel microdystrophin protein that includes the functional elements of the C-Terminal (CT) domain found in naturally occurring dystrophin. RGX-202 uses REGENXBIO's proprietary NAV® AAV8 vector. |
Rockville’s RegenxBio promotes 2 senior executives as it enters ‘next phase of growth’RegenxBio Inc. is making changes in its executive ranks as it enters what its CEO calls “the next phase of growth.” The Rockville biotech, which is developing treatments for retinal and neurodegenerative diseases, said this week it has expanded the roles of two executives within the C-suite. Curran Simpson, chief technology and operations officer, has been promoted to chief operating officer — a position that will also absorb his existing duties. |
REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONSREGENXBIO Inc. (Nasdaq: RGNX) today announced the promotion of Curran Simpson from Chief Technology and Operations Officer to Chief Operating Officer. In addition, Shiva Fritsch has been elevated to Chief Communications Officer and will continue in her role as Chief People Officer. |
REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceREGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. |
RGNX Price Returns
| 1-mo | 1.36% |
| 3-mo | -3.14% |
| 6-mo | -25.48% |
| 1-year | -10.07% |
| 3-year | -48.20% |
| 5-year | -21.86% |
| YTD | 1.98% |
| 2022 | -30.64% |
| 2021 | -27.91% |
| 2020 | 10.72% |
| 2019 | -2.34% |
| 2018 | 26.17% |
Loading social stream, please wait...